You are here: Industry Insights > glioblastoma

News List

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma prnasia
December 06, 2021
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy...
UK trial to assess Sativex for the treatment of ‘aggressive’ brain tumours pharmatimes
August 06, 2021
A new UK-based trial is set to assess the efficacy of GW Pharma’s cannabis-based drug Sativex as a potential treatment for patients with a recurrent glioblastoma – the most aggressive form of brain tumours.
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma prnasia
June 16, 2021
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II ...
OncoSynergy Announces First Patient Treated in OS2966 Trial of Recurrent Glioblastoma americanpharmaceuticalreview
March 10, 2021
OncoSynergy announced the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.
IGV-001 demonstrates success against glioblastoma in Phase Ib trial europeanpharmaceuticalreview
January 28, 2021
Imvax’s Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma has shown positive results.
First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma americanpharmaceuticalreview
January 15, 2021
Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ...
Innovent Announces NMPA Approves BYVASDA for Adult Recurrent Glioblastoma americanpharmaceuticalreview
January 08, 2021
Innovent Biologics has announced BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of ...
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma prnasia
December 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA® ...
AIVITA Biomedical's Glioblastoma Trial Shows Improved Progression Free Survival americanpharmaceuticalreview
December 02, 2020
AIVITA Biomedical announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM).
Pelareorep-based combination therapy improves glioblastoma patient survival europeanpharmaceuticalreview
November 26, 2020
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and temozolomide increased progression-free survival by an average of eight months.

Previous page 1 2 3 4 Next page